{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "d49104e2",
   "metadata": {},
   "outputs": [],
   "source": [
    "import os, re, sys\n",
    "import numpy as np\n",
    "import pickle as pkl"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "d06eae30",
   "metadata": {},
   "outputs": [],
   "source": [
    "input_folder = \"../data/preprocessed_tika/\"\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "a3cc57d1",
   "metadata": {},
   "outputs": [],
   "source": [
    "sys.path.append(\"../train/\")\n",
    "\n",
    "from simulation_classifier_annotations import annotations"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "b07ee5ff",
   "metadata": {},
   "outputs": [],
   "source": [
    "file_to_text = {}\n",
    "for root, folder, files in os.walk(input_folder):\n",
    "    for file_name in files:\n",
    "        if not file_name.endswith(\"pkl\"):\n",
    "            continue\n",
    "        pdf_file = re.sub(\".pkl\", \"\", file_name)\n",
    "        \n",
    "        full_file = input_folder + \"/\" + file_name\n",
    "#         print (full_file)\n",
    "        with open(full_file, 'rb') as f:\n",
    "            text = pkl.load(f)\n",
    "        file_to_text[pdf_file] = text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "faf47569",
   "metadata": {},
   "outputs": [],
   "source": [
    "sap_regex = re.compile(r\"(?i)statistical\\s*analysis\\s*plan\")\n",
    "\n",
    "sap_regex = re.compile(r\"(?i)\\bSAP\\b\")\n",
    "\n",
    "sap_regex = re.compile(r\"(?i)\\bdata\\s*analysis\\s*plan\\b\")\n",
    "\n",
    "sap_regex = re.compile(r\"(?i)\\bDAP\\b\")\n",
    "\n",
    "\n",
    "sap_regex = re.compile(r\"(?i)\\b(simulations?)\\b\")\n",
    "sap_regex = re.compile(r\"(?i)\\b(scenarios?|simulations?|tmle|estimation|simulated?s?|simulating|finite sample|sampled|bayesian|monte carlo|kolmogorov)\\b\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "2a42af5b",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'\\n\\t\\nStatistical\\tanalysis\\tplan,\\tdated\\t14\\tDecember\\t2016 \\n\\n'"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "file_to_text[\"TB-TB-2018-M-P-A.pdf\"][146]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "ea435dfe",
   "metadata": {},
   "outputs": [],
   "source": [
    "#  Annotations are page number (zero-indexed)\n",
    "annotations = {\n",
    "    'TB-TB-2018-DAR-PIA.pdf': [],\n",
    "    'TB-TB-2018-M-P-A.pdf': [],\n",
    "    'HIV-HIV-2016-Ayles-A Study of the HIV prevention Trials Network.pdf': [80],\n",
    "    'TB-TB-2019-T-A-b.pdf': [],\n",
    "    'HIV-HIV-2016-Laufer-Trimethoprim-Sulfamethoxazole-Chloroquine.pdf': [],\n",
    "    'NTD-Filariasis-2019-Weil-DOLF IDA Papua New Guinea.pdf': [],\n",
    "    'HIV-HIV-2017-Abrams-IMPAACT P1101.pdf': [92, 94],  # Monte Carlo simulations\n",
    "    'NUT-A-2019-M-T.pdf': [],\n",
    "    'HIV-HIV-2018-IMPAACT-P1112.pdf': [],  # Uses simulation/Monte Carlo for PK not for sample size\n",
    "    'EDD-rotavirus-2017-Isanaka-ROSE.pdf': [],\n",
    "    'NTD-Y-2019-M-Y.pdf': [],\n",
    "    'NTD-Chagas-2015-Morillo-BENEFIT.pdf': [],\n",
    "    'MAT-V-2018-R-M.pdf': [], # page 31 (30 zero-indexed) has a graph of detectable z-score vs sample size but this does not look like it is simulation-derived.\n",
    "    'HIV-HIV-2018-GSK1265744.pdf': [], # Uses simulation for dose but not sample size\n",
    "    \"POL-P-2018-O-A-L.pdf\": [],\n",
    "    'MAT-Hypothermia-2018-Hansen-Electricity-free Infant Warmer.pdf': [], # light   bulbs to simulate an infant‚Äôs metabolism\n",
    "    'EDD-T-2019-S-T.pdf': [],\n",
    "    'NTD-Hookwork-2018-Keiser-Efficacy and safety of a single.pdf': [],\n",
    "    'TB-TB-2018-Piazza-A Phase 1b, Randomized, Double-blind.pdf': [],\n",
    "    'MAL-Malaria-2019-Llanos-Cuentas-Tafenoquine vs. Primaquine to.pdf': [],\n",
    "    'HIV-HIV-2017-Corey-HVTN703-HPTN081.pdf': [45, 47, 51],\n",
    "    # These power calculations are conducted using the open source R package seqDesign developed by the protocol statisticians [117], which computes power based on simulating many thousands of efficacy trials, applying  the sequential monitoring procedures to each trial, and computing power as the  fraction of the trials where the 1-sided 0.025-level Wald test rejects the null  hypothesis. The calculations are based on a large number of simulated efficacy  trials.\n",
    "    'MAL-M-2019-A-S.pdf': [63],\n",
    "    # least 80% power using 10,000 simulations with the data from Sumba\n",
    "    'NTD-E-2017-A-A.pdf': [],\n",
    "    'HIV-HIV-2017-Bekker-HVTN100.pdf': [52, 53],  # omputer simulations (details provided below)\n",
    "    'MAL-Malaria-2019-Tinto-Extension to study MALARIA-055 PRI.pdf': [],\n",
    "    'NUT-NUT-2019-A-I.pdf': [],\n",
    "    # 'HIV-HIV-2018-M-A.pdf': [], # image based PDF - exclude from dataset\n",
    "    'HIV-HIV-2017-L-I.pdf': [],\n",
    "    'TB-TB-2019-M-A.pdf': [],\n",
    "    'VAC-G-2016-VAC-G-2016-V.pdf': [],\n",
    "    'HIV-HIV-2016-N-S.pdf': [], #  Uses simulation but not for sample size\n",
    "    'VAC-Shigellosis-2019-Raqib-Shigella WRSS1 Vaccine trial in Bangladesh.pdf': [],\n",
    "    'HIV-HIV-2017-Evolocumab-AMG145.pdf': [],\n",
    "    'TB-TB-2015-D-A.pdf': [], # Using the sample size calculation formula\n",
    "    'POL-P-2016-G-T.pdf': [],\n",
    "    'TB-TB-2019-Suliman-A Phase I_IIa Double-Blind.pdf': [],\n",
    "    # 'MAT-Anemia-2015-Etheredge-Prenatal Iron Supplements Safety and.pdf': [],\n",
    "    # 'HIV-HIV-2016-R-E.pdf': [],\n",
    "    'HIV-HIV-2019-H-S.pdf': [57, 63, 136, 138, 144, 169, 170, 172, 175, 176, 180, 181, 182, 183, 184, 186, 189, 192, 193, 194, 199, 206, 209, 212, 215, 238], # a lot of this seems to deal with simulation for sample size\n",
    "    # 'NTD-Filariasis-2019-Weil-DOLF IDA Haiti.pdf': [],\n",
    "    # 'MAT-MAT-2018-G-F.pdf': [],\n",
    "    # 'EDD-R-2017-G-V.pdf': [],\n",
    "    'MAT-HIV-2016-Fowler-PROMISE.pdf': [22, 118, 119, 351, 539, 776], # Not sure - need to revisit\n",
    "    'TB-TB-2018-H-A.pdf': [54, 137],\n",
    "    'HIV-HIV-2016-HVTN114.pdf': [33],\n",
    "    'HIV-HIV-2018-Long-acting Cabotegravir Plus Long-acting Rilpivirine.pdf': [], # Not sure\n",
    "    'NUT-S-2018-R-S.pdf': [95], # Unsure - see p 95 (zero indexed)\n",
    "    # 'VAC-Tdap-2019-Sancovski-A Post-marketing, Observational, Retrospective.pdf': [],\n",
    "    'NTD-t-2017-M-E.pdf': [],\n",
    "    # 'HIV-HIV-2018-Lockman-Dolutegravir-Containing versus Efavirenz-Containing Antiretroviral Therapy.pdf': [],\n",
    "    # 'MAL-M-2018-D-C.pdf': [],\n",
    "    # 'NTD-D-2017-S-P.pdf': [],\n",
    "    'HIV-HIV-2016-Garrett-HVTN108.pdf': [52], # These simulations are based on 10,000 simulated datasets and use an exchangeable correlation structure between responses with pairwise     correlations of 0.3\n",
    "    # 'HIV-HIV-2018-Labhardt-CASCADE.pdf': [],\n",
    "    # 'TB-TB-2019-Dawson-A Phase 2 Open‚ÄêLabel Partially .pdf': [],\n",
    "    # 'MAL-MAL-2018-Dorsey-PROMOTE Birth Cohort 1.pdf': [],\n",
    "    # 'PNE-P-2019-C-P.pdf': [],\n",
    "    # 'HIV-HIV-2019-Venter-ADVANCE.pdf': [],\n",
    "    # 'HIV-HIV-2019-K-C.pdf': [],\n",
    "    'PNE-Pneumonia-2019-Alexander-LEAP2.pdf': [48, 49],  # Monte Carlo simulation were utilized\n",
    "    # 'MAT-Cervical Disease-2019-Greene-LEEP.pdf': [],\n",
    "    'TB-TB-2018-Churchyard-Bedaquiline-Delamanid.pdf': [73],\n",
    "    # 'MAL-Malaria-2019-Foy-RIMDAMAL.pdf': [],\n",
    "    # 'TB-TB-2019-N-S.pdf': [],\n",
    "    # 'NUT-Stunting-2019-Humphrey-SHINE.pdf': [],\n",
    "    'PNE-Pneumonia-2018-Keenan-Mortality Reduction After Oral Azithromycin.pdf': [],\n",
    "    # Use Monte Carlo but only for analysis, not for sample size planning\n",
    "    'EDD-Cholera-2016-Qadri-Shanchol.pdf': [], # Kolmogorov used but not for sample size - just for Bayesian p-values.\n",
    "    # 'TB-TB-2020-John-Stewart-iTIPS.pdf': [],\n",
    "    # 'VAC-Ecoli-2019-Qadri-ETVAX.pdf': [],\n",
    "    'HIV-HIV-2018-Havlir-SEARCH.pdf': [65, 66, 73],  # We will also using Monte Carlo multi-variable simulations to estimate\n",
    "    # 'HIV-HIV-2016-Kurth-High-yield HIV testing, facilitated linkage to care.pdf': []\n",
    "    'HIV-HIV-2017-Corey-HVTN704-HPTN085.pdf': [42, 43, 48],\n",
    "    # 'HIV-HIV-2016_Tebas-A5354.pdf': [],\n",
    "    # 'HIV-HIV-2016-Weinberg-NICHP1091.pdf': [],\n",
    "    # 'MAL-Malaria-2016-Valencia-Phase 1 and 2a Clinical.pdf': [],\n",
    "    # 'NTD-Filariasis-2019-Weil-DOLF IDA Indonesia.pdf': [],\n",
    "    # 'VAC-M-2015-L-W.pdf': []\n",
    "}\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "0807f26e",
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "TB-TB-2018-DAR-PIA.pdf 68\n",
      "TB-TB-2018-M-P-A.pdf 161\n",
      "HIV-HIV-2016-Ayles-A Study of the HIV prevention Trials Network.pdf 166\n",
      "TB-TB-2019-T-A-b.pdf 389\n",
      "\t 387 \t lford, Alvan R. Feinstein. A  simulation study of the number of eve\n",
      "HIV-HIV-2016-Laufer-Trimethoprim-Sulfamethoxazole-Chloroquine.pdf 100\n",
      "NTD-Filariasis-2019-Weil-DOLF IDA Papua New Guinea.pdf 90\n",
      "HIV-HIV-2017-Abrams-IMPAACT P1101.pdf 85\n",
      "NUT-A-2019-M-T.pdf 196\n",
      "HIV-HIV-2018-IMPAACT-P1112.pdf 155\n",
      "EDD-rotavirus-2017-Isanaka-ROSE.pdf 210\n",
      "NTD-Y-2019-M-Y.pdf 66\n",
      "NTD-Chagas-2015-Morillo-BENEFIT.pdf 76\n",
      "MAT-V-2018-R-M.pdf 193\n",
      "HIV-HIV-2018-GSK1265744.pdf 124\n",
      "\t 53 \t l Pharmacology Modelling and  Simulation (CPMS) at GlaxoSmithKline.\n",
      "POL-P-2018-O-A-L.pdf 97\n",
      "MAT-Hypothermia-2018-Hansen-Electricity-free Infant Warmer.pdf 56\n",
      "\t 23 \t in an   environmental chamber simulating room temperature (about 22\n",
      "\t 23 \t   2. Estimated use: This test simulates conditions of the pad in us\n",
      "\t 23 \t mall (3.8 W) light   bulbs to simulate an infant‚Äôs metabolism, and \n",
      "\t 23 \t d two light cotton towels (to simulate the weight of a   light blan\n",
      "EDD-T-2019-S-T.pdf 105\n",
      "NTD-Hookwork-2018-Keiser-Efficacy and safety of a single.pdf 51\n",
      "TB-TB-2018-Piazza-A Phase 1b, Randomized, Double-blind.pdf 56\n",
      "MAL-Malaria-2019-Llanos-Cuentas-Tafenoquine vs. Primaquine to.pdf 402\n",
      "HIV-HIV-2017-Corey-HVTN703-HPTN081.pdf 193\n",
      "MAL-M-2019-A-S.pdf 92\n",
      "NTD-E-2017-A-A.pdf 60\n",
      "HIV-HIV-2017-Bekker-HVTN100.pdf 154\n",
      "MAL-Malaria-2019-Tinto-Extension to study MALARIA-055 PRI.pdf 100\n",
      "NUT-NUT-2019-A-I.pdf 132\n",
      "HIV-HIV-2018-M-A.pdf 182\n",
      "HIV-HIV-2017-L-I.pdf 148\n",
      "TB-TB-2019-M-A.pdf 115\n",
      "VAC-G-2016-VAC-G-2016-V.pdf 48\n",
      "HIV-HIV-2016-N-S.pdf 358\n",
      "VAC-Shigellosis-2019-Raqib-Shigella WRSS1 Vaccine trial in Bangladesh.pdf 64\n",
      "HIV-HIV-2017-Evolocumab-AMG145.pdf 95\n",
      "TB-TB-2015-D-A.pdf 124\n",
      "POL-P-2016-G-T.pdf 62\n",
      "TB-TB-2019-Suliman-A Phase I_IIa Double-Blind.pdf 75\n",
      "MAT-Anemia-2015-Etheredge-Prenatal Iron Supplements Safety and.pdf 46\n",
      "HIV-HIV-2016-R-E.pdf 452\n",
      "HIV-HIV-2019-H-S.pdf 242\n",
      "\t 58 \t ol groups, we also performed  simulations to investigate the perfor\n",
      "\t 58 \t ffect size. By this method of simulation, the coefficient of variat\n",
      "\t 58 \t ns from the assumptions, the  simulations suggested that the sample\n",
      "\t 213 \t members at t = {1, 2}.  Given simulated data under both study arms,\n",
      "NTD-Filariasis-2019-Weil-DOLF IDA Haiti.pdf 67\n",
      "MAT-MAT-2018-G-F.pdf 60\n",
      "EDD-R-2017-G-V.pdf 125\n",
      "MAT-HIV-2016-Fowler-PROMISE.pdf 902\n",
      "\t 181 \t ntepartum treatment arm.    A simulation project (details available\n",
      "\t 187 \t l alternative approaches in a simulation study (details available u\n",
      "\t 429 \t el is a widely  published HIV simulation model, which incorporates \n",
      "\t 429 \t state- transition Monte Carlo simulation of HIV disease in adults a\n",
      "\t 429 \t h of the main randomizations, simulations will be conducted to   \n",
      "\t 588 \t partum  treatment arm.      A simulation project (details available\n",
      "\t 595 \t   alternative approaches in a simulation study (details available u\n",
      "\t 686 \t el is a widely  published HIV simulation model, which incorporates \n",
      "\t 686 \t state- transition Monte Carlo simulation of HIV disease in adults a\n",
      "\t 686 \t h of the main randomizations, simulations will be conducted to  und\n",
      "TB-TB-2018-H-A.pdf 365\n",
      "HIV-HIV-2016-HVTN114.pdf 126\n",
      "HIV-HIV-2018-Long-acting Cabotegravir Plus Long-acting Rilpivirine.pdf 242\n",
      "\t 241 \t V-infected Subjects \tFigure 4 Simulated* Median (90% Prediction Int\n",
      "\t 241 \t  female population) \tFigure 8 Simulated* Median (90% Prediction Int\n",
      "\t 241 \t -infected Subjects \tFigure 10 Simulated* Median (90% PI) RPV Plasma\n",
      "\t 241 \t men (900 mg IM Day \tFigure 11 Simulated Median (90% PI) RPV Profile\n",
      "\t 241 \t  Day 1 of ATLAS-2M \tFigure 12 Simulated Median (90% PI) RPV Plasma \n",
      "\t 241 \t d Q8W thereafter^) \tFigure 13 Simulated Median RPV Plasma Concentra\n",
      "\t 241 \t n to a Q8W regimen \tFigure 14 Simulated* Median (90% PI) RPV Plasma\n",
      "NUT-S-2018-R-S.pdf 113\n",
      "VAC-Tdap-2019-Sancovski-A Post-marketing, Observational, Retrospective.pdf 82\n",
      "NTD-t-2017-M-E.pdf 118\n",
      "HIV-HIV-2018-Lockman-Dolutegravir-Containing versus Efavirenz-Containing Antiretroviral Therapy.pdf 163\n",
      "MAL-M-2018-D-C.pdf 74\n",
      "NTD-D-2017-S-P.pdf 85\n",
      "HIV-HIV-2016-Garrett-HVTN108.pdf 155\n",
      "HIV-HIV-2018-Labhardt-CASCADE.pdf 90\n",
      "TB-TB-2019-Dawson-A Phase 2 Open‚ÄêLabel Partially .pdf 112\n",
      "MAL-MAL-2018-Dorsey-PROMOTE Birth Cohort 1.pdf 94\n",
      "PNE-P-2019-C-P.pdf 91\n",
      "HIV-HIV-2019-Venter-ADVANCE.pdf 184\n",
      "HIV-HIV-2019-K-C.pdf 191\n",
      "PNE-Pneumonia-2019-Alexander-LEAP2.pdf 175\n",
      "MAT-Cervical Disease-2019-Greene-LEEP.pdf 296\n",
      "TB-TB-2018-Churchyard-Bedaquiline-Delamanid.pdf 119\n",
      "MAL-Malaria-2019-Foy-RIMDAMAL.pdf 58\n",
      "TB-TB-2019-N-S.pdf 224\n",
      "NUT-Stunting-2019-Humphrey-SHINE.pdf 91\n",
      "PNE-Pneumonia-2018-Keenan-Mortality Reduction After Oral Azithromycin.pdf 184\n",
      "\t 162 \t ysis will be conducted using  simulation. If the conditional power \n",
      "EDD-Cholera-2016-Qadri-Shanchol.pdf 124\n",
      "TB-TB-2020-John-Stewart-iTIPS.pdf 85\n",
      "VAC-Ecoli-2019-Qadri-ETVAX.pdf 65\n",
      "HIV-HIV-2018-Havlir-SEARCH.pdf 101\n",
      "HIV-HIV-2016-Kurth-High-yield HIV testing, facilitated linkage to care.pdf 111\n",
      "HIV-HIV-2017-Corey-HVTN704-HPTN085.pdf 175\n",
      "HIV-HIV-2016_Tebas-A5354.pdf 133\n",
      "HIV-HIV-2016-Weinberg-NICHP1091.pdf 93\n",
      "MAL-Malaria-2016-Valencia-Phase 1 and 2a Clinical.pdf 61\n",
      "NTD-Filariasis-2019-Weil-DOLF IDA Indonesia.pdf 108\n",
      "VAC-M-2015-L-W.pdf 193\n"
     ]
    }
   ],
   "source": [
    "r1 = re.compile(r\"(?i)sample\\s*size\")\n",
    "r2 = re.compile(r\"(?i)simulat\")\n",
    "lastm1 = []\n",
    "lastm2 = []\n",
    "lastpage = \"\"\n",
    "for file, pages in file_to_text.items():\n",
    "    print (file, len(pages))\n",
    "    for page_no, page_text in enumerate(pages):\n",
    "#         if \"sample\" not in page_text.lower():\n",
    "#             continue\n",
    "        if page_no in annotations.get(file, []):\n",
    "            continue\n",
    "        m1 = list(r1.finditer(page_text))\n",
    "        m2 = list(r2.finditer(page_text))\n",
    "        if (len(m1) > 0 and len(lastm2) > 0) or (len(lastm1) > 0 and len(m2) > 0):      \n",
    "            for match in m2:\n",
    "                l = int(np.max((0, match.start() - 30)))\n",
    "                r = int(np.min((len(page_text), match.end() + 30)))\n",
    "                print (\"\\t\", page_no, \"\\t\",  page_text[l:r].replace(\"\\n\", \" \"))\n",
    "            for match in lastm2:\n",
    "                l = int(np.max((0, match.start() - 30)))\n",
    "                r = int(np.min((len(lastpage), match.end() + 30)))\n",
    "                print (\"\\t\", page_no, \"\\t\",  lastpage[l:r].replace(\"\\n\", \" \"))    \n",
    "        lastm1 = m1\n",
    "        lastm2 = m2\n",
    "        lastpage = page_text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "94f412d0",
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "TB-TB-2018-DAR-PIA.pdf 68\n",
      "TB-TB-2018-M-P-A.pdf 161\n",
      "HIV-HIV-2016-Ayles-A Study of the HIV prevention Trials Network.pdf 166\n",
      "TB-TB-2019-T-A-b.pdf 389\n",
      "HIV-HIV-2016-Laufer-Trimethoprim-Sulfamethoxazole-Chloroquine.pdf 100\n",
      "NTD-Filariasis-2019-Weil-DOLF IDA Papua New Guinea.pdf 90\n",
      "HIV-HIV-2017-Abrams-IMPAACT P1101.pdf 85\n",
      "NUT-A-2019-M-T.pdf 196\n",
      "HIV-HIV-2018-IMPAACT-P1112.pdf 155\n",
      "EDD-rotavirus-2017-Isanaka-ROSE.pdf 210\n",
      "NTD-Y-2019-M-Y.pdf 66\n",
      "NTD-Chagas-2015-Morillo-BENEFIT.pdf 76\n",
      "MAT-V-2018-R-M.pdf 193\n",
      "HIV-HIV-2018-GSK1265744.pdf 124\n",
      "POL-P-2018-O-A-L.pdf 97\n",
      "MAT-Hypothermia-2018-Hansen-Electricity-free Infant Warmer.pdf 56\n",
      "EDD-T-2019-S-T.pdf 105\n",
      "NTD-Hookwork-2018-Keiser-Efficacy and safety of a single.pdf 51\n",
      "TB-TB-2018-Piazza-A Phase 1b, Randomized, Double-blind.pdf 56\n",
      "MAL-Malaria-2019-Llanos-Cuentas-Tafenoquine vs. Primaquine to.pdf 402\n",
      "HIV-HIV-2017-Corey-HVTN703-HPTN081.pdf 193\n",
      "\t 63 \t aximum likelihood estimation (tMLE) will be used to estimate cum\n",
      "\t 63 \t ls of   implementation of the tMLE estimators in an automated an\n",
      "\t 63 \t mAb group/control) of these   tMLE estimators. Point estimates a\n",
      "\t 132 \t  tenofovir   TG transgender   tMLE targeted maximum likelihood e\n",
      "MAL-M-2019-A-S.pdf 92\n",
      "NTD-E-2017-A-A.pdf 60\n",
      "HIV-HIV-2017-Bekker-HVTN100.pdf 154\n",
      "MAL-Malaria-2019-Tinto-Extension to study MALARIA-055 PRI.pdf 100\n",
      "NUT-NUT-2019-A-I.pdf 132\n",
      "HIV-HIV-2018-M-A.pdf 182\n",
      "HIV-HIV-2017-L-I.pdf 148\n",
      "TB-TB-2019-M-A.pdf 115\n",
      "VAC-G-2016-VAC-G-2016-V.pdf 48\n",
      "HIV-HIV-2016-N-S.pdf 358\n",
      "VAC-Shigellosis-2019-Raqib-Shigella WRSS1 Vaccine trial in Bangladesh.pdf 64\n",
      "HIV-HIV-2017-Evolocumab-AMG145.pdf 95\n",
      "TB-TB-2015-D-A.pdf 124\n",
      "POL-P-2016-G-T.pdf 62\n",
      "TB-TB-2019-Suliman-A Phase I_IIa Double-Blind.pdf 75\n",
      "MAT-Anemia-2015-Etheredge-Prenatal Iron Supplements Safety and.pdf 46\n",
      "HIV-HIV-2016-R-E.pdf 452\n",
      "HIV-HIV-2019-H-S.pdf 242\n",
      "\t 56 \t a ùëó-specific individual level TMLE can be applied to a  pooled d\n",
      "\t 176 \t maximum likelihood estimator (TMLE), based on iterated condition\n",
      "\t 179 \t inimum loss-based estimation (TMLE) to provide an unbiased and m\n",
      "\t 179 \t the unadjusted estimator. The TMLE for Œ®(Pn0 ) is given by the f\n",
      "\t 179 \t ptive pair-matched trial, the TMLE for Œ®(Pn0 ) can be implemente\n",
      "\t 180 \t alidation selector and in the TMLE. Logistic regression can prov\n",
      "\t 180 \t  unadjusted estimator and the TMLE are asymptotically linear and\n",
      "\t 180 \t  unadjusted estimator and the TMLE are given by the difference i\n",
      "\t 180 \t te is through adjustment with TMLE.  Inference for the intervent\n",
      "\t 180 \t f the influence curve for the TMLE. Confidence intervals and two\n",
      "\t 181 \t the analysis. Adjustment with TMLE should improve power by reduc\n",
      "\t 183 \t d estimation was based on the TMLE, adjusting for a single covar\n",
      "\t 183 \t imator and about 95% with the TMLE.  3. With increasing heteroge\n",
      "\t 183 \t ly attenuated with use of the TMLE.  1.5 2.0 2.5 3.0  0 .6  0 .7\n",
      "\t 183 \t ator. Blue corresponds to the TMLE, adjusting for 1 baseline com\n",
      "\t 186 \t sted estimator as well as the TMLE with data-adaptive selection \n",
      "\t 186 \t  influence curve, and for the TMLE, inference was based on a cro\n",
      "\t 188 \t  unadjusted estimator and the TMLE, using cross-validation with \n",
      "\t 189 \t pendix.  Unadjusted Estimator TMLE bias std. err. tstat cover po\n",
      "\t 189 \t  unadjusted estimator and the TMLE over 500 simulated trials whe\n",
      "\t 189 \t ngness.  Unadjusted Estimator TMLE bias std. err. tstat cover Œ± \n",
      "\t 189 \t  unadjusted estimator and the TMLE over 500 simulated trials whe\n",
      "\t 193 \t uation.  Unadjusted Estimator TMLE bias std. err. tstat cover Œ± \n",
      "\t 194 \t tudy arm Unadjusted Estimator TMLE  bias std. err. tstat cover Œ±\n",
      "\t 194 \t tudy arm Unadjusted Estimator TMLE  bias std. err. tstat cover Œ±\n",
      "\t 194 \t mators.  Unadjusted Estimator TMLE bias std. err. tstat cover po\n",
      "\t 194 \t  unadjusted estimator and the TMLE, when there were a mixture of\n",
      "\t 206 \t aximum likelihood estimation (TMLE) to estimate  EWE [ I ‚à£‚à£C = 0\n",
      "\t 208 \t inimum loss-based estimation (TMLE) to provide an unbiased and m\n",
      "\t 208 \t the unadjusted estimator. The TMLE for the sample incidence rati\n",
      "\t 208 \t wing substitution estimator:  TMLE = œàÃÇ‚àó(1)  œàÃÇ‚àó(0) =  1 J  ‚àëJ j\n",
      "\t 208 \t ation to select the candidate TMLE, with candidate selected to m\n",
      "\t 209 \t  the unadjusted estimator and TMLE are asymptotically linear and\n",
      "\t 209 \t f the influence curve for the TMLE is given by  ÀÜIC(a; OÃÑk) = 1 \n",
      "\t 209 \t e influence curve for the log(TMLE) =log[œàÃÇ‚àó(1)/œàÃÇ‚àó(0)] for matc\n",
      "\t 209 \t timator is a specific case of TMLE, where we replace the targete\n",
      "\t 210 \t the analysis. Adjustment with TMLE should improve power by reduc\n",
      "\t 214 \t  unadjusted estimator and the TMLE. Both estimators were unbiase\n",
      "\t 215 \t  gain with adjustment through TMLE. The attained power ranged fr\n",
      "\t 215 \t d and from 88 to 91% with the TMLE. Throughout, there was nomina\n",
      "\t 215 \t ewhere.  Unadjusted Estimator TMLE  bias std. err. tstat cover p\n",
      "\t 215 \t  unadjusted estimator and the TMLE over 500 simulated trials. Th\n",
      "\t 216 \t ed individual interval- level TMLE, with the exposure of interes\n",
      "\t 216 \t  with pooled individual-level TMLE with the community treated as\n",
      "\t 217 \t . For the latter, we will use TMLE to adjust for ways in which i\n",
      "\t 218 \t r incomplete measurement with TMLE to adjust for ways in which i\n",
      "\t 218 \t ing a pooled individual-level TMLE with community included as a \n",
      "\t 222 \t d HIV RNA levels. We will use TMLE to adjust for potentially dif\n",
      "\t 223 \t effect with a community-level TMLE using data-adaptive selection\n",
      "\t 223 \t on of the time point-specific TMLE-based population suppression \n",
      "\t 223 \t Estimation will be based on a TMLE that pools over individuals a\n",
      "\t 223 \t eath and out-migration, using TMLE to adjust for potentially non\n",
      "\t 224 \t  with pooled individual-level TMLE, adjusted for community as a \n",
      "\t 224 \t fect, using a community-level TMLE analogous to that used to com\n",
      "\t 225 \t  level TMLE, adjusted for community as a \n",
      "\t 225 \t y informative censoring using TMLE. We will plot the resulting s\n",
      "\t 225 \t fect, using a community-level TMLE analogous to that used to com\n",
      "\t 225 \t  with pooled individual-level TMLE,  28  \n",
      "\t 228 \t on. A pooled individual-level TMLE including community as a fixe\n",
      "\t 228 \t tween arms, using a two stage TMLE, weighting person-time equall\n",
      "\t 228 \t tween arms, using a two stage TMLE weighting person-time equally\n",
      "\t 228 \t  Kaplan-Meier estimators, and TMLE of baseline HIV-status-specif\n",
      "\t 229 \t e compared between arms using TMLE, weighting individuals equall\n",
      "\t 229 \t ated risks between arms using TMLE, weighting individuals equall\n",
      "\t 230 \t  with pooled individual-level TMLE, using the community as the i\n",
      "\t 231 \t ity using an individual-level TMLE, adjusting for incomplete mea\n",
      "\t 232 \t rtions will be estimated with TMLE, adjusting for incomplete mea\n",
      "\t 233 \t ith a pooled individual-level TMLE, adjusted for community as a \n",
      "\t 233 \t t.  Primary analyses will use TMLE to adjust for potentially dif\n",
      "NTD-Filariasis-2019-Weil-DOLF IDA Haiti.pdf 67\n",
      "MAT-MAT-2018-G-F.pdf 60\n",
      "EDD-R-2017-G-V.pdf 125\n",
      "MAT-HIV-2016-Fowler-PROMISE.pdf 902\n",
      "TB-TB-2018-H-A.pdf 365\n",
      "HIV-HIV-2016-HVTN114.pdf 126\n",
      "HIV-HIV-2018-Long-acting Cabotegravir Plus Long-acting Rilpivirine.pdf 242\n",
      "NUT-S-2018-R-S.pdf 113\n",
      "VAC-Tdap-2019-Sancovski-A Post-marketing, Observational, Retrospective.pdf 82\n",
      "NTD-t-2017-M-E.pdf 118\n",
      "HIV-HIV-2018-Lockman-Dolutegravir-Containing versus Efavirenz-Containing Antiretroviral Therapy.pdf 163\n",
      "MAL-M-2018-D-C.pdf 74\n",
      "NTD-D-2017-S-P.pdf 85\n",
      "HIV-HIV-2016-Garrett-HVTN108.pdf 155\n",
      "HIV-HIV-2018-Labhardt-CASCADE.pdf 90\n",
      "TB-TB-2019-Dawson-A Phase 2 Open‚ÄêLabel Partially .pdf 112\n",
      "MAL-MAL-2018-Dorsey-PROMOTE Birth Cohort 1.pdf 94\n",
      "PNE-P-2019-C-P.pdf 91\n",
      "HIV-HIV-2019-Venter-ADVANCE.pdf 184\n",
      "HIV-HIV-2019-K-C.pdf 191\n",
      "PNE-Pneumonia-2019-Alexander-LEAP2.pdf 175\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "MAT-Cervical Disease-2019-Greene-LEEP.pdf 296\n",
      "TB-TB-2018-Churchyard-Bedaquiline-Delamanid.pdf 119\n",
      "MAL-Malaria-2019-Foy-RIMDAMAL.pdf 58\n",
      "TB-TB-2019-N-S.pdf 224\n",
      "NUT-Stunting-2019-Humphrey-SHINE.pdf 91\n",
      "PNE-Pneumonia-2018-Keenan-Mortality Reduction After Oral Azithromycin.pdf 184\n",
      "EDD-Cholera-2016-Qadri-Shanchol.pdf 124\n",
      "TB-TB-2020-John-Stewart-iTIPS.pdf 85\n",
      "VAC-Ecoli-2019-Qadri-ETVAX.pdf 65\n",
      "HIV-HIV-2018-Havlir-SEARCH.pdf 101\n",
      "HIV-HIV-2016-Kurth-High-yield HIV testing, facilitated linkage to care.pdf 111\n",
      "HIV-HIV-2017-Corey-HVTN704-HPTN085.pdf 175\n",
      "\t 60 \t ximum  likelihood estimation (tMLE) will be used to estimate cum\n",
      "\t 60 \t ails of implementation of the tMLE  estimators in an automated a\n",
      "\t 60 \t  (mAb group/control) of these tMLE estimators. Point estimates a\n",
      "\t 121 \t FV tenofovir  TG transgender  tMLE targeted maximum likelihood e\n",
      "HIV-HIV-2016_Tebas-A5354.pdf 133\n",
      "HIV-HIV-2016-Weinberg-NICHP1091.pdf 93\n",
      "MAL-Malaria-2016-Valencia-Phase 1 and 2a Clinical.pdf 61\n",
      "NTD-Filariasis-2019-Weil-DOLF IDA Indonesia.pdf 108\n",
      "VAC-M-2015-L-W.pdf 193\n"
     ]
    }
   ],
   "source": [
    "sap_regex = re.compile(r\"(?i)\\btmle\\b\")\n",
    "for file, pages in file_to_text.items():\n",
    "#     if file in annotations:\n",
    "#         continue\n",
    "    print (file, len(pages))\n",
    "    for page_no, page_text in enumerate(pages):\n",
    "#         if \"sample\" not in page_text.lower():\n",
    "#             continue\n",
    "        matches = sap_regex.finditer(page_text)\n",
    "               \n",
    "        for match in matches:\n",
    "            l = int(np.max((0, match.start() - 30)))\n",
    "            r = int(np.min((len(page_text), match.end() + 30)))\n",
    "            print (\"\\t\", page_no, \"\\t\",  page_text[l:r].replace(\"\\n\", \" \"))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "id": "9322eba9",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "77"
      ]
     },
     "execution_count": 32,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(files)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "dafcb96e",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.7"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
